TransMedics Group (NASDAQ:TMDX) Coverage Initiated at Robert W. Baird

Investment analysts at Robert W. Baird initiated coverage on shares of TransMedics Group (NASDAQ:TMDX) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The brokerage set an “outperform” rating and a $200.00 price target on the stock. Robert W. Baird’s target price suggests a potential upside of 34.88% from the company’s current price.

A number of other research analysts also recently weighed in on the company. Piper Sandler raised their price target on TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Stephens lifted their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Needham & Company LLC initiated coverage on TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price for the company. TD Cowen lifted their target price on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Finally, Oppenheimer lifted their price target on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.30.

TransMedics Group Price Performance

Shares of TMDX stock opened at $148.28 on Tuesday. The stock’s fifty day moving average is $156.02 and its 200-day moving average is $130.77. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The stock has a market capitalization of $4.95 billion, a PE ratio of -436.12 and a beta of 1.99. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. The firm had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company’s quarterly revenue was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. Equities research analysts expect that TransMedics Group will post 1.23 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,948,714.31. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. The disclosure for this sale can be found here. Insiders have sold a total of 61,247 shares of company stock valued at $9,650,880 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. grew its holdings in shares of TransMedics Group by 21.3% in the fourth quarter. Principal Financial Group Inc. now owns 21,929 shares of the company’s stock worth $1,731,000 after acquiring an additional 3,858 shares during the period. D.A. Davidson & CO. lifted its holdings in TransMedics Group by 7.1% in the fourth quarter. D.A. Davidson & CO. now owns 9,220 shares of the company’s stock valued at $728,000 after acquiring an additional 608 shares during the period. Hsbc Holdings PLC increased its position in TransMedics Group by 19.0% in the fourth quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock worth $3,287,000 after buying an additional 6,650 shares in the last quarter. Axiom Investors LLC DE increased its position in TransMedics Group by 83.2% in the fourth quarter. Axiom Investors LLC DE now owns 83,750 shares of the company’s stock worth $6,610,000 after buying an additional 38,029 shares in the last quarter. Finally, Alpha DNA Investment Management LLC purchased a new stake in TransMedics Group in the fourth quarter worth about $500,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.